You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 5, 2024

Details for Belgium Supplementary Protection Certificate: 2016C/032


✉ Email this page to a colleague

« Back to Dashboard


Country Patent Number Supplementary Protection Certificate SPC Country SPC Description SPC Expiration
European Patent Office 2101777 2016C/032 Belgium PRODUCT NAME: AMBRISENTAN EN COMBINAISON AVEC LE TADALAFIL; AUTHORISATION NUMBER AND DATE: EU/1/08/451 20151125 ⤷  Sign Up

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.